Pharmacy benefit managers inflate drug prices and decrease competition while consumers pay the price. Does the FTC have the medicine to fix it?

Our CEO Chris Blackley writes in MedCity News about the FTC’s new probe into the big pharmacy benefit managers, or PBMs. “Because PBMs have created market distortion in price and prevented a more efficient market from developing, people can’t shop for the drugs they need. Co-pays are sometimes more expensive than paying in cash, patients increasingly can’t afford their medication, and pharmacies are struggling to survive.” See more of Chris’s take on MedCity News.